Biogen Inc.

NASDAQ: BIIB · Real-Time Price · USD
131.09
1.30 (1.00%)
At close: Jun 02, 2025, 3:59 PM
130.56
-0.40%
After-hours: Jun 02, 2025, 06:44 PM EDT

Biogen Revenue Breakdown

Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Fumarate Revenue 1.6B 1.59B 2B 2.36B 3.91B 2.1B 2.36B 883.7M 4.6M 1.89B 1.96B 1.53B 1.14B 1.08B 900.2M
Fumarate Revenue Growth +0.40% -20.45% -15.45% -39.51% +85.81% -11.05% +167.40% +19110.87% -99.76% -3.75% +28.37% +34.39% +5.22% +19.92% n/a
Interferon Revenue 968M 1.11B 1.31B 1.57B 1.88B 8.53B 8.6B 1.97B 1.96B n/a n/a n/a n/a n/a n/a
Interferon Revenue Growth -12.45% -15.30% -16.65% -16.59% -77.99% -0.77% +335.62% +0.47% n/a n/a n/a n/a n/a n/a n/a
MS Product Revenues Revenue 4.35B 4.66B 5.43B 6.1B 7.83B 2.1B 1.72B n/a n/a n/a n/a n/a n/a n/a n/a
MS Product Revenues Revenue Growth -6.69% -14.15% -10.93% -22.16% +273.49% +21.62% n/a n/a n/a n/a n/a n/a n/a n/a n/a
SPINRAZA Revenue 1.57B 1.74B 1.79B 1.91B 2.05B 1.89B 1.86B n/a n/a n/a n/a n/a n/a n/a n/a
SPINRAZA Revenue Growth -9.65% -2.92% -5.86% -7.16% +8.45% +1.51% n/a n/a n/a n/a n/a n/a n/a n/a n/a
TYSABRI product Revenue 1.72B 1.88B 2.03B 2.06B 1.95B n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
TYSABRI product Revenue Growth -8.63% -7.58% -1.56% +6.01% n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a

Revenue by Geography

Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015 Dec 31, 2014 Dec 31, 2013 Dec 31, 2012 Dec 31, 2011 Dec 31, 2010
Non-Us Revenue 3.98B 3.14B 3.47B 3.81B 5.9B 6.71B 1.9B 3.34B 2.77B 2.64B 2.64B 3.58B 1.99B 1.88B 1.74B
Non-Us Revenue Growth +26.57% -9.45% -8.84% -35.50% -12.12% +252.73% -42.97% +20.60% +4.72% +0.23% -26.37% +80.01% +5.74% +7.85% n/a
United States Revenue 2.19B n/a n/a n/a n/a n/a n/a 3.29B 3.17B 2.91B 2.43B n/a 2.18B 1.95B n/a
United States Revenue Growth n/a n/a n/a n/a n/a n/a n/a +3.93% +8.98% +19.85% n/a n/a +11.36% n/a n/a

Operating Expense Breakdown

Period Ending Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jun 30, 2018 Mar 31, 2018 Dec 31, 2017 Sep 30, 2017 Jun 30, 2017 Mar 31, 2017 Dec 31, 2016 Sep 30, 2016 Jun 30, 2016 Mar 31, 2016 Dec 31, 2015 Sep 30, 2015 Jun 30, 2015 Mar 31, 2015
Selling, General, and Administrative Revenue 572.5M 680M 588.4M 553.8M 581.5M 608.5M 788.2M 548M 605M 632.8M 563.3M 572.6M 634.9M 787.9M 654.1M 637.3M 595M 806.3M 573.1M 555.1M 570.1M 664.9M 554.5M 587.6M 567.7M 591.1M 497.7M 516.2M 501.3M 572.4M 433.8M 430.2M 499.1M 495.5M 462.7M 492.4M 497.3M 583M 477.83M 491.89M 560.36M
Selling, General, and Administrative Revenue Growth -15.81% +15.57% +6.25% -4.76% -4.44% -22.80% +43.83% -9.42% -4.39% +12.34% -1.62% -9.81% -19.42% +20.46% +2.64% +7.11% -26.21% +40.69% +3.24% -2.63% -14.26% +19.91% -5.63% +3.51% -3.96% +18.77% -3.58% +2.97% -12.42% +31.95% +0.84% -13.80% +0.73% +7.09% -6.03% -0.99% -14.70% +22.01% -2.86% -12.22% n/a
Research and Development Revenue 434.1M 532.3M 542.7M 513.9M 445.4M 647.5M 736.3M 584.2M 570.6M 601.6M 549.2M 528.6M 551.7M 699.5M 702.4M 585.1M 514.2M 1.73B 1.14B 647.6M 476.3M 691.7M 540.4M 484.8M 563.7M 611.6M 507.9M 981M 496.7M 587.6M 446.4M 796.2M 423.4M 533.9M 529M 473.1M 437.3M 541.7M 519.86M 490.73M 460.55M
Research and Development Revenue Growth -18.45% -1.92% +5.60% +15.38% -31.21% -12.06% +26.04% +2.38% -5.15% +9.54% +3.90% -4.19% -21.13% -0.41% +20.05% +13.79% -70.21% +51.28% +76.17% +35.96% -31.14% +28.00% +11.47% -14.00% -7.83% +20.42% -48.23% +97.50% -15.47% +31.63% -43.93% +88.05% -20.70% +0.93% +11.82% +8.19% -19.27% +4.20% +5.94% +6.55% n/a